The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.

The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.

Date of Patent:
Mar. 30, 2021

Filed:

Oct. 08, 2018
Applicant:

Boehringer Ingelheim Animal Health Usa Inc., Duluth, GA (US);

Inventors:

Luis Alejandro Hernandez, Story City, IA (US);

Christine Margaret Muehlenthaler, Ames, IA (US);

Eric Martin Vaughn, Ames, IA (US);

Gregory Haiwick, Ankeny, IA (US);

Assignee:

Other;

Attorneys:
Primary Examiner:
Int. Cl.
CPC ...
C07K 14/005 (2006.01); A61K 39/12 (2006.01); C12P 21/02 (2006.01); C12N 7/00 (2006.01); A61K 39/00 (2006.01);
U.S. Cl.
CPC ...
C07K 14/005 (2013.01); A61K 39/12 (2013.01); C12N 7/00 (2013.01); C12P 21/02 (2013.01); A61K 39/00 (2013.01); A61K 2039/5256 (2013.01); A61K 2039/5258 (2013.01); A61K 2039/53 (2013.01); C12N 2710/14043 (2013.01); C12N 2750/10022 (2013.01); C12N 2750/10023 (2013.01); C12N 2750/10034 (2013.01); C12N 2750/10051 (2013.01); C12N 2799/026 (2013.01);
Abstract

Vaccination methods to control PCV2 infection with different PCV2 subtypes are disclosed. Specifically, a PCV2 subtype b (PCV2b) ORF2 proteins or immunogenic compositions comprising a PCV2b ORF2 protein are used in a method for the treatment or prevention of an infection with PCV2 of the same PCV2b and/or different subtype; the reduction, prevention or treatment of clinical signs caused by an infection with PCV2 of the same PCV2b or a different subtype; and/or the prevention or treatment of a disease caused by an infection with PCV2 of the same PCV2b and/or a different subtype. The present invention in particular relates to PCV2 subtype b (PCV2b) ORF2 proteins characterized in that they contain at least one mutation in the BC loop that such that the expressed protein is preferably expressed in a higher amount compared to a PCV2 ORF2 protein that does not contain such mutation.


Find Patent Forward Citations

Loading…